S&P Global Announces Successful Completion of its Acquisition of ORBCOMM's Automatic Identification System Business — Neutral
SPGI PRNewsWire — November 10, 2025Acquisition will strengthen S&P Global's maritime analytics and global trade intelligence offerings and support its global supply chain strategy NEW YORK , Nov. 10, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the successful completion of its acquisition of ORBCOMM's Automatic Identification System (AIS) business. The AIS business is a leading provider of satellite data services used to track and monitor vessels, enhancing maritime visibility and delivering critical insights that support business intelligence and decision-making for clients worldwide.
KBR Investors Have Opportunity to Lead KBR, Inc. Securities Fraud Lawsuit with the Schall Law Firm — Neutral
KBR GlobeNewsWire — November 10, 2025LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against KBR, Inc. (“KBR” or “the Company”) (NYSE: KBR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 6, 2025 and June 19, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 18, 2025.
iHeartMedia and TikTok Partner to Launch First-of-Its-Kind, Multiplatform Partnership — Neutral
IHRT Business Wire — November 10, 2025NEW YORK--(BUSINESS WIRE)--iHeartMedia, the leading audio company in America, and TikTok, the world's leading destination for short-form mobile video, today announced a groundbreaking, multiplatform partnership that will bring TikTok creators into iHeart's ecosystem. This collaboration includes the launch of the TikTok Podcast Network, which will feature up to 25 new podcasts hosted by TikTok creators, as well as a national broadcast and digital radio channel, and a series of live event integra.
Keysight Validates First PTCRB New Radio Non-Terrestrial Networks Conformance Test Cases — Neutral
KEYS Business Wire — November 10, 2025SANTA ROSA, Calif.--(BUSINESS WIRE)--Keysight Technologies, Inc. (NYSE: KEYS) has validated the first PCS Type Certification Review Board (PTCRB) 5G new radio (NR) non-terrestrial networks (NTN) test cases for 3rd Generation Partnership Project (3GPP) Release 17 (Rel-17) under PTCRB RFT-555. Keysight currently leads in the total number of radio frequency (RF) transmitter and receiver test cases and uniquely holds validated performance test cases. These are the first NR-NTN validations within a.
Agnico Eagle Rallies 106% YTD: Should You Buy the Stock Now? — Positive
AEM Zacks Investment Research — November 10, 2025AEM's 106% YTD rally, strong cash flows and project progress suggest more upside, backed by higher gold prices.
Is the Options Market Predicting a Spike in Taylor Morrison Home Stock? — Neutral
TMHC Zacks Investment Research — November 10, 2025Investors need to pay close attention to TMHC stock based on the movements in the options market lately.
OPAL FUELS INC (OPAL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now — Positive
OPAL Zacks Investment Research — November 10, 2025OPAL FUELS INC (OPAL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bears are Losing Control Over Dell Technologies (DELL), Here's Why It's a 'Buy' Now — Negative
DELL Zacks Investment Research — November 10, 2025Dell Technologies (DELL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Believe Omnicell (OMCL) Could Rally 34.53%: Here's is How to Trade — Positive
OMCL Zacks Investment Research — November 10, 2025The consensus price target hints at a 34.5% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kennametal (KMT) Just Flashed Golden Cross Signal: Do You Buy? — Positive
KMT Zacks Investment Research — November 10, 2025Kennametal Inc. (KMT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KMT's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Wall Street Analysts Predict a 45.88% Upside in OppFi (OPFI): Here's What You Should Know — Positive
OPFI Zacks Investment Research — November 10, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 45.9% in OppFi (OPFI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now — Negative
MESO Zacks Investment Research — November 10, 2025After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99% — Positive
ANRO Zacks Investment Research — November 10, 2025The consensus price target hints at a 62% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MacroGenics (MGNX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? — Neutral
MGNX Zacks Investment Research — November 10, 2025After losing some value lately, a hammer chart pattern has been formed for MacroGenics (MGNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Does Onestream (OS) Have the Potential to Rally 25.9% as Wall Street Analysts Expect? — Positive
OS Zacks Investment Research — November 10, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 25.9% in Onestream (OS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher — Neutral
PALI Zacks Investment Research — November 10, 2025After losing some value lately, a hammer chart pattern has been formed for Palisade Bio (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Believe OrthoPediatrics (KIDS) Could Rally 41.92%: Here's is How to Trade — Positive
KIDS Zacks Investment Research — November 10, 2025The consensus price target hints at a 41.9% upside potential for OrthoPediatrics (KIDS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Chime Financial, Inc. (CHYM) Have the Potential to Rally 52.06% as Wall Street Analysts Expect? — Positive
CHYM Zacks Investment Research — November 10, 2025The consensus price target hints at a 52.1% upside potential for Chime Financial, Inc. (CHYM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? — Positive
KROS Zacks Investment Research — November 10, 2025The consensus price target hints at a 42.8% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.